These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
433 related articles for article (PubMed ID: 11509936)
21. A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I-II trial. Sao H; Kitaori K; Kasai M; Shimokawa T; Kato C; Yamanishi H; Ueda R; Morishima Y Int J Hematol; 1999 Jan; 69(1):27-35. PubMed ID: 10641440 [TBL] [Abstract][Full Text] [Related]
22. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation. Atkinson K; Downs K Bone Marrow Transplant; 1995 Dec; 16(6):755-8. PubMed ID: 8750265 [TBL] [Abstract][Full Text] [Related]
23. The predictive value of helper T lymphocyte precursor frequencies for graft-versus-host disease and graft-versus-leukaemia effects in allogeneic bone marrow transplantation. Russell CA; Heilmann C; Madsen HO; Vindeløv LL Bone Marrow Transplant; 2001 May; 27(9):949-58. PubMed ID: 11436105 [TBL] [Abstract][Full Text] [Related]
24. Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients. Mehta J; Singhal S; Gee AP; Chiang KY; Godder K; Rhee Fv Fv; DeRienzo S; O'Neal W; Lamb L; Henslee-Downey PJ Bone Marrow Transplant; 2004 Feb; 33(4):389-96. PubMed ID: 14716338 [TBL] [Abstract][Full Text] [Related]
25. Decreased incidence of graft-versus-host disease and improved survival with methotrexate combined with cyclosporin compared with monotherapy in recipients of bone marrow from donors other than HLA identical siblings. Ringdén O; Klaesson S; Sundberg B; Ljungman P; Lönnqvist B; Persson U Bone Marrow Transplant; 1992 Jan; 9(1):19-25. PubMed ID: 1543946 [TBL] [Abstract][Full Text] [Related]
26. [Prophylaxis with FK-506 for graft-versus-host disease after transplantation of bone marrow from unrelated donors]. Hamazaki T; Yagi K; Inoue M; Sakata N; Okamura T; Yasui M; Sasabe M; Kishimoto T; Inoue A; Kawa K Rinsho Ketsueki; 2000 May; 41(5):430-6. PubMed ID: 10879106 [TBL] [Abstract][Full Text] [Related]
27. Graft-versus-host disease in children: the AIEOP-BMT Group experience with cyclosporin A. Locatelli F; Uderzo C; Dini G; Zecca M; Arcese W; Messina C; Andolina M; Miniero R; Porta F; Rovelli A Bone Marrow Transplant; 1993 Dec; 12(6):627-33. PubMed ID: 8136746 [TBL] [Abstract][Full Text] [Related]
28. Long-time survival after unrelated bone marrow transplantation in children and adolescents and targeted therapy with CD25 blockade to prevent GVHD. Wawer A; Laws HJ; Dilloo D; Göbel U; Burdach S Klin Padiatr; 2004; 216(3):169-75. PubMed ID: 15175962 [TBL] [Abstract][Full Text] [Related]
30. Early (day -7) versus conventional (day -1) inception of cyclosporine-A for graft-versus-host disease prophylaxis after unrelated donor hematopoietic stem cell transplantation in children. Long-term results of an AIEOP prospective, randomized study. Lanino E; Rondelli R; Locatelli F; Messina C; Pession A; Balduzzi A; Favre C; Santarone S; Rabusin M; Pollichieni S; Cesaro S; Dini G; Biol Blood Marrow Transplant; 2009 Jun; 15(6):741-8. PubMed ID: 19450759 [TBL] [Abstract][Full Text] [Related]
31. Helper T-lymphocyte precursor frequency predicts the occurrence of graft-versus-host disease and disease relapse after allogeneic bone marrow transplantation from HLA-identical siblings. Leung AY; Kwok J; Lie AK; Chen P; Chen FE; Liang R Haematologica; 2001 Jun; 86(6):652-6. PubMed ID: 11418376 [TBL] [Abstract][Full Text] [Related]
32. Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major. Ghavamzadeh A; Iravani M; Ashouri A; Mousavi SA; Mahdavi N; Shamshiri A; Hadjibabaie M; Namdar R; Nedaeifard L; Ghaffari H; Alimoghaddam K Biol Blood Marrow Transplant; 2008 Mar; 14(3):301-8. PubMed ID: 18275896 [TBL] [Abstract][Full Text] [Related]
33. Single-centre experience with allogeneic bone marrow transplantation for acute lymphoblastic leukaemia in childhood: similar survival after matched-related and matched-unrelated donor transplants. Al-Kasim FA; Thornley I; Rolland M; Lau W; Tsang R; Freedman MH; Saunders EF; Calderwood S; Doyle JJ Br J Haematol; 2002 Feb; 116(2):483-90. PubMed ID: 11841456 [TBL] [Abstract][Full Text] [Related]
34. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Carlens S; Ringdén O; Remberger M; Lönnqvist B; Hägglund H; Klaesson S; Mattsson J; Svahn BM; Winiarski J; Ljungman P; Aschan J Bone Marrow Transplant; 1998 Oct; 22(8):755-61. PubMed ID: 9827972 [TBL] [Abstract][Full Text] [Related]
35. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia]. Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125 [TBL] [Abstract][Full Text] [Related]
36. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft. Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494 [TBL] [Abstract][Full Text] [Related]
37. Tacrolimus as monotherapy or combined with minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation: long-term outcomes. Uberti JP; Ayash L; Braun T; Reynolds C; Silver S; Ratanatharathorn V Bone Marrow Transplant; 2004 Sep; 34(5):425-31. PubMed ID: 15273705 [TBL] [Abstract][Full Text] [Related]
38. Do corticosteroids add any benefit to standard GVHD prophylaxis in allogeneic BMT? Ancín I; Ferrá C; Gallardo D; Peris J; Berlanga J; Gonzalez JR; Virgili N; Grañena A Bone Marrow Transplant; 2001 Jul; 28(1):39-45. PubMed ID: 11498742 [TBL] [Abstract][Full Text] [Related]
39. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Cutler C; Kim HT; Hochberg E; Ho V; Alyea E; Lee SJ; Fisher DC; Miklos D; Levin J; Sonis S; Soiffer RJ; Antin JH Biol Blood Marrow Transplant; 2004 May; 10(5):328-36. PubMed ID: 15111932 [TBL] [Abstract][Full Text] [Related]
40. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR; Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]